Global Tumor NGS Detection Supply, Demand and Key Producers, 2023-2029

Global Tumor NGS Detection Supply, Demand and Key Producers, 2023-2029

The global Tumor NGS Detection market size is expected to reach $ 5059.4 million by 2029, rising at a market growth of 15.1% CAGR during the forecast period (2023-2029).

The main purpose of NGS is to discover clinically treatable genetic variants and guide patient treatment.

This report studies the global Tumor NGS Detection demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Tumor NGS Detection, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumor NGS Detection that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Tumor NGS Detection total market, 2018-2029, (USD Million)

Global Tumor NGS Detection total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Tumor NGS Detection total market, key domestic companies and share, (USD Million)

Global Tumor NGS Detection revenue by player and market share 2018-2023, (USD Million)

Global Tumor NGS Detection total market by Type, CAGR, 2018-2029, (USD Million)

Global Tumor NGS Detection total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Tumor NGS Detection market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, Sinopharm Group, Fosunpharma, Novogene, Geneseeq and AmoyDx, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Tumor NGS Detection market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Tumor NGS Detection Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Tumor NGS Detection Market, Segmentation by Type
Medical Equipment
Consumables

Global Tumor NGS Detection Market, Segmentation by Application
Companion Diagnostics
Early Cancer Screening
Drug Discovery
Other

Companies Profiled:
Agilent
Thermo Fisher Scientific
BGI Group
Roche Foundation Medicine
Sinopharm Group
Fosunpharma
Novogene
Geneseeq
AmoyDx
Burning Rock Medicine
Perkin Elmer
Qiagen NV
Partek
Illumina Inc.
Pacific Biosciences of California Inc.
Life Technologies Corporation
GTH.O
Paradigm Diagnostics
Oxford Nanopore Technologies Ltd.
Eurofins Scientific S.E.

Key Questions Answered

1. How big is the global Tumor NGS Detection market?

2. What is the demand of the global Tumor NGS Detection market?

3. What is the year over year growth of the global Tumor NGS Detection market?

4. What is the total value of the global Tumor NGS Detection market?

5. Who are the major players in the global Tumor NGS Detection market?

6. What are the growth factors driving the market demand?